ORBIMED ADVISORS LLC
Q4 2022 13F-HR Holdings
Net value change ($000)
-159,542
(-3.0%)
New positions
8
Sold out positions
22
Turnover %
9.9%
Sector allocation + QoQ delta (equities-only)
Holdings aggregated across other managers listed in the original SEC filing. View detailed breakdown
Snapshot: Change Analysis
Compared to Q3 2022
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| UNH | 66,786 | 49.5% |
| CMPX | 62,414 | 124.7% |
| VRNA | 61,273 | 105.3% |
| ISRG | 57,303 | 53.4% |
| PCVX | 44,296 | 257.1% |
| IRON | 42,981 | NEW |
| IONS | 41,290 | 121.4% |
| TERN | 33,499 | 76.0% |
| SYK | 31,905 | 37.2% |
| BSX | 29,393 | 19.5% |
Top Reduces (Value $000, Stocks/ETFs)
| Tricida, Inc. | -107,744 | -100.0% |
| ARGX | -89,081 | -93.6% |
| Third Harmonic Bio, Inc. | -84,779 | -77.3% |
| ABBV | -80,526 | -100.0% |
| GH | -53,421 | -100.0% |
| ALNY | -50,140 | -100.0% |
| PFE | -42,324 | -37.2% |
| Mirati Therapeutics, Inc. | -40,931 | -41.3% |
| ACET | -39,321 | -37.1% |
| VRTX | -29,652 | -27.4% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
4,843
(0.1% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|